User doing PRP with exosomes for hair loss, sees possible regrowth after two treatments. Another user suggests providing before and after pictures for better assessment.
PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.
The user experienced hair thinning from chromium and alpha lipoic acid supplements, which stopped after discontinuing them. Someone mentioned this could be telogen effluvium, a temporary condition.
Someone's two-month progress using oral minoxidil (2.5mg ED) to treat hair loss, which has resulted in thicker eyebrows and eyelashes but no scalp changes or shedding.
The user experienced hair thinning and was diagnosed with alopecia incognito and male pattern baldness. They are using minoxidil, finasteride, and dutasteride scalp injections, reporting gradual improvement with no side effects.
The user experienced significant hair regrowth using topical minoxidil 5% twice daily and 1mg finasteride daily, along with microstamping every 14 days. They reported initial shedding but achieved satisfying results by month four, with minimal side effects.
The user reports a stable receding hairline with new hair growth after using 5% minoxidil, 1mg oral finasteride, D-Biotin daily, derma rolling twice a week, and three PRP sessions per month. They plan to update their progress in four months.
A user is trying 2-deoxy-D-ribose with distilled water for hair growth, observing new hair and skin pigmentation changes. Others compare it to Minoxidil, expressing interest and caution about its effectiveness and safety.
A user expressed concern about using low-dose topical finasteride while conceiving, but was reassured that the risk of affecting a fetus is negligible. The user stopped using finasteride during pregnancy and switched to minoxidil and ketoconazole, while others shared experiences and advice on using these treatments safely.
Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.
A 33-year-old man using finasteride, minoxidil, thickening shampoo, conditioner, and Nizoral noticed peach fuzz after a month and is hopeful for regrowth. Others shared mixed experiences, with some seeing further growth and others not.
The user has been experiencing diffuse hair thinning despite using finasteride, minoxidil, dermarolling, clobetasol cream, and PRP sessions. They seek advice on additional treatments and are advised to check vitamin D, iron, and thyroid levels.
The user experienced increased hair density and improved hairline definition after 8 months of using 1mg finasteride and 5mg minoxidil (both oral and topical) daily, though the hairline recession hasn't reversed. They noticed fuller eyelashes and increased shedding, but overall hair growth is outpacing the loss.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
A sugar gel is claimed to spark hair regrowth, but users express skepticism, noting that minoxidil and finasteride remain the most effective treatments. Many users joke about frequent "breakthroughs" that work on rats but not humans, and some mention the potential of PP405 as a future treatment.
Hair loss treatment using 1.25 Finasteride Teva daily, Folcare Minoxidil 5% 2x a day, dermarolling, Nizoral, Hask biotin boost shampoo, and 5000mg biotin pill. User unsure if experiencing regrowth or just growth, especially in crown area.
The post discusses a user's 6-month progress using topical finasteride (0.08%) and minoxidil (5%) once a day, combined with scalp micropigmentation (SMP). The user hopes for improved hair growth as they let their hair grow out.
A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
The user is using RU58841 for hair regrowth on the temples and is considering adding minoxidil. They are questioning the potential for vellus hairs to develop into fuller hair and the possibility of reactivating dormant follicles.
KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.
PP405 is expected to be a promising addition to hair loss treatments, potentially working well with existing treatments like finasteride and minoxidil, but not as a standalone solution. Users are hopeful for its effectiveness, especially in combination with other treatments, though expectations vary.
The user experienced significant hair growth and increased density after using 1.1mg finasteride for 4-5 weeks and switching from topical to oral minoxidil (3mg) for 3 weeks. They reported no shedding and were uncertain if the growth was due to the oral minoxidil or finasteride.
The user is experiencing increased hair shedding and is concerned about regression despite consistent use of finasteride, minoxidil, and other treatments. The consensus is that this is likely a temporary shedding phase, and adjustments to the dermarolling frequency are suggested.
The user reports using Finasteride 1.1 mg, Minoxidil 3 mg, Biotin daily, and occasionally a dermapen from May 24 to July 22. They observe some improvement in hair regrowth, especially around the temples and crown.
A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.
PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.
PP405 may help with hair regrowth, especially when combined with minoxidil and finasteride, but its long-term effectiveness is unclear. Phase 3 trials are expected to begin soon, with results in a few years.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.